Table 1 Clinical and demographic data for studied cases
From: Clinical impact of IDH1 mutations and MGMT methylation in adult glioblastoma
Factors | Non-neuro-oncological patients (n = 20) | GBM (n = 58) |
|---|---|---|
Age (Mean) | ||
< 60 ψεαρσ | 20 (100%) | 42 (72.4%) |
≥ 60 years | 0 (0%) | 16 (27.6%) |
X2 = 6.9, P = 0.008 | ||
Gender | ||
Male | 10 (50%) | 35 (60.3%) |
Female | 10 (50%) | 22 (39.7%) |
Pathology | GBM (Grade IV) | |
ECGO | ||
< 2 | 19 (32.8%) | |
2 | 39 (67.2%) | |
Tumor site | ||
Lt | 29 (50%) | |
Right | 23 (39.7%) | |
Multiple | 6 (10.3%) | |
Tumor size | ||
< 5χμ | 22 (37.9%) | |
≥ 5 cm | 36 (62.1%) | |
Surgical intervention | ||
Biopsy | 36 (62.1%) | |
Resection | ||
Total | 19 (32.8%) | |
Sub-total | 3 (5.2%) | |